Medexus Pharmaceuticals Stock Performance
| MDP Stock | 2.61 0.12 4.40% |
The company secures a Beta (Market Risk) of -0.52, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Medexus Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Medexus Pharmaceuticals is likely to outperform the market. At this point, Medexus Pharmaceuticals has a negative expected return of -0.021%. Please make sure to verify Medexus Pharmaceuticals' potential upside, and the relationship between the total risk alpha and daily balance of power , to decide if Medexus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Medexus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Medexus Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 5.3 M | |
| Total Cashflows From Investing Activities | -6 M |
Medexus |
Medexus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 273.00 in Medexus Pharmaceuticals on May 10, 2025 and sell it today you would lose (12.00) from holding Medexus Pharmaceuticals or give up 4.4% of portfolio value over 90 days. Medexus Pharmaceuticals is producing return of less than zero assuming 3.248% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than Medexus Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medexus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medexus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medexus Pharmaceuticals, and traders can use it to determine the average amount a Medexus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0065
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MDP |
Estimated Market Risk
| 3.25 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medexus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medexus Pharmaceuticals by adding Medexus Pharmaceuticals to a well-diversified portfolio.
Medexus Pharmaceuticals Fundamentals Growth
Medexus Stock prices reflect investors' perceptions of the future prospects and financial health of Medexus Pharmaceuticals, and Medexus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medexus Stock performance.
| Return On Equity | 0.0545 | |||
| Return On Asset | 0.0455 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 106.57 M | |||
| Shares Outstanding | 32.26 M | |||
| Price To Book | 1.23 X | |||
| Price To Sales | 0.82 X | |||
| Revenue | 108.33 M | |||
| EBITDA | 18.94 M | |||
| Cash And Equivalents | 23.97 M | |||
| Total Debt | 36.98 M | |||
| Book Value Per Share | 1.62 X | |||
| Cash Flow From Operations | 24.03 M | |||
| Earnings Per Share | 0.11 X | |||
| Total Asset | 171.84 M | |||
| Retained Earnings | (61.99 M) | |||
About Medexus Pharmaceuticals Performance
By examining Medexus Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Medexus Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medexus Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about Medexus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Medexus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medexus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medexus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Medexus Pharmaceuticals has high historical volatility and very poor performance |
- Analyzing Medexus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medexus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Medexus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medexus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medexus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medexus Pharmaceuticals' stock. These opinions can provide insight into Medexus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.